VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Tuesday. The brokerage issued a sell rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Trading Down 5.6 %

Shares of VNRX stock opened at $0.68 on Tuesday. The company’s 50-day moving average price is $0.68 and its 200-day moving average price is $0.68. The stock has a market cap of $63.01 million, a price-to-earnings ratio of -1.70 and a beta of 1.10. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23.

VolitionRx (NYSE:VNRX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.34 million. As a group, equities research analysts predict that VolitionRx will post -0.31 EPS for the current year.

Insiders Place Their Bets

In other VolitionRx news, Director Guy Archibald Innes bought 150,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average cost of $0.67 per share, with a total value of $100,500.00. Following the acquisition, the director now directly owns 406,683 shares of the company’s stock, valued at $272,477.61. The trade was a 58.44 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 12.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.